Guard Therapeutics Q2 FY26 pretax loss narrows to SEK 4.36 million

• Guard Therapeutics posted a net loss of SEK 4.36 million in Q2, narrowing from SEK 32.22 million a year earlier.
• Loss per share narrowed to SEK 0.22 from SEK 1.66; net sales remained at no revenue.
• Operating loss improved to SEK 4.51 million from SEK 32.82 million, as R&D costs fell to SEK 18,000 from SEK 29.74 million.
• Cash and cash equivalents declined to SEK 34.11 million at June 30 from SEK 100.48 million a year earlier; equity ratio rose 2 percentage points to 81%.
• Signed a conditional reverse takeover of Disruptive Pharma Holding; deal closed July 27, shifting focus to Formulite with new CEO Peter Åsberg.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guard Therapeutics International AB (publ) published the original content used to generate this news brief on August 19, 2026, and is solely responsible for the information contained therein.